Rhythm Pharmaceuticals Q1 revenue rises 84%

Rhythm Pharmaceuticals

05/05/2026 12:36

Overview

U.S. biopharma's Q1 product revenue rose 83.8% yr/yr on IMCIVREE uptake

Q1 net loss came in slightly wider than analyst expectations

Company launched IMCIVREE for acquired hypothalamic obesity in U.S. and Europe, Japan review ongoing

Outlook

Company expects 2026 non-GAAP operating expenses of $385 mln to $415 mln

Rhythm expects Japan PMDA decision on IMCIVREE in acquired HO in second half of 2026

Company says launches in Europe for acquired HO anticipated in 2027

Result Drivers

IMCIVREE LAUNCHES - Q1 revenue growth was primarily driven by the launch of IMCIVREE for acquired hypothalamic obesity in the U.S. and continued uptake for Bardet-Biedl syndrome, per co

Company press release: ID:nGNX8jxRHj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
$60.11 mln
Q1 Net Income
Slight Miss*
-$55.64 mln
-$55.27 mln (12 Analysts)
Q1 Operating Income
-$52.36 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $140.00, about 63.6% above its May 4 closing price of $85.58

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)